Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
GNVC [NASD]
GenVec, Inc.
Index- P/E- EPS (ttm)-0.19 Insider Own1.50% Shs Outstand17.28M Perf Week-5.02%
Market Cap39.23M Forward P/E- EPS next Y-0.37 Insider Trans0.00% Shs Float15.48M Perf Month-19.22%
Income-3.10M PEG- EPS next Q-0.09 Inst Own37.70% Short Float0.35% Perf Quarter-31.83%
Sales4.30M P/S9.12 EPS this Y79.20% Inst Trans3.13% Short Ratio0.78 Perf Half Y18.85%
Book/sh0.73 P/B3.11 EPS next Y-5.70% ROA-21.10% Target Price8.50 Perf Year7.08%
Cash/sh0.73 P/C3.09 EPS next 5Y35.00% ROE-25.00% 52W Range1.61 - 4.67 Perf YTD9.13%
Dividend- P/FCF- EPS past 5Y39.00% ROI-19.50% 52W High-51.39% Beta2.17
Dividend %- Quick Ratio8.30 Sales past 5Y-15.50% Gross Margin- 52W Low40.99% ATR0.14
Employees11 Current Ratio8.30 Sales Q/Q-81.00% Oper. Margin-72.10% RSI (14)35.86 Volatility7.17% 5.53%
OptionableNo Debt/Eq0.00 EPS Q/Q-28.60% Profit Margin-72.10% Rel Volume0.19 Prev Close2.26
ShortableYes LT Debt/Eq0.00 EarningsMay 08 Payout- Avg Volume69.70K Price2.27
Recom2.00 SMA20-6.78% SMA50-17.59% SMA200-9.75% Volume13,170 Change0.44%
Feb-24-14Initiated HC Wainwright Buy $9
May-20-15 01:04PM  GENVEC INC Financials
May-14-15 08:00AM  GenVec Highlights Proprietary Gorilla Vectors At ASGCT Presentation PR Newswire
May-10-15 08:11PM  10-Q for GenVec, Inc. at Company Spotlight
May-08-15 09:48AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:30AM  GenVec Reports First Quarter 2015 Financial Results PR Newswire
May-01-15 08:11PM  10-K for GenVec, Inc. at Company Spotlight
Apr-23-15 01:57PM  GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers
Apr-22-15 08:25AM  Michael Richman Appointed To GenVec Board Of Directors at noodls
08:00AM  Michael Richman Appointed To GenVec Board Of Directors PR Newswire
Apr-21-15 08:29AM  GenVec Announces Collaboration with the Laboratory of Malaria Immunology & Vaccinology at noodls +5.69%
08:01AM  GenVec Announces Collaboration with the Laboratory of Malaria Immunology & Vaccinology PR Newswire
Apr-16-15 02:57PM  Bristol-Myers Deal Flags Three Gene-Therapy Picks at Barrons.com
Mar-30-15 09:07AM  GenVec to Release Fourth Quarter and Year-End 2014 Financial Results and Conduct a Conference Call on March 24, 2015 at noodls -5.16%
09:07AM  GenVec To Present At The 27th Annual ROTH Conference at noodls
09:07AM  GenVec Reports Fourth Quarter And 2014 Year-End Financial Results at noodls
09:07AM  GenVec and TheraBiologics form Collaboration to Develop Neural Stem Cell Mediated Cancer Therapies at noodls
Mar-24-15 10:00AM  GenVec Inc Earnings Call scheduled for 10:00 am ET today
08:40AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:07AM  Q4 2014 GenVec Inc Earnings Release - Before Market Open
07:00AM  GenVec Reports Fourth Quarter And 2014 Year-End Financial Results PR Newswire
Mar-23-15 07:00AM  GenVec and TheraBiologics form Collaboration to Develop Neural Stem Cell Mediated Cancer Therapies PR Newswire
Mar-17-15 08:00AM  GenVec to Release Fourth Quarter and Year-End 2014 Financial Results and Conduct a Conference Call on March 24, 2015 PR Newswire
Mar-02-15 08:00AM  GenVec To Present At The 27th Annual ROTH Conference PR Newswire
Feb-25-15 11:02AM  Video Interview: Doug Swirsky, Chief Executive Officer, GenVec, Inc. [GNVC] GlobeNewswire
Feb-02-15 08:00AM  GenVec To Present At The 17th Annual BIO CEO & Investor Conference PR Newswire +14.45%
Jan-07-15 07:00PM  Lady Gaga at High Volume Drives Hearing-Loss Drug Search: Health at Bloomberg +23.68%
Dec-09-14 04:53PM  GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Security
Nov-14-14 07:09PM  10-Q for GenVec, Inc. Company Spotlight
Nov-12-14 09:29AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:18AM  GenVec Reports Third Quarter 2014 Financial Results at noodls
07:55AM  GenVec Reports Third Quarter 2014 Financial Results PR Newswire
Nov-11-14 07:30AM  Preclinical Data For GenVec's RSV Vaccine Candidate Presented At The 9th RSV Symposium PR Newswire +8.84%
Nov-05-14 07:15AM  GenVec Achieves Milestone In Hearing And Balance Collaboration PR Newswire
Nov-03-14 04:16PM  GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online +7.45%
Oct-31-14 07:30AM  Quinterol Mallette Appointed to GenVec Board Of Directors PR Newswire
Oct-29-14 06:30AM  GENVEC INC Files SEC form 8-K, Other Events EDGAR Online
Oct-20-14 09:27AM  GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:00AM  Zola P. Horovitz To Retire From GenVec Board PR Newswire
Aug-12-14 09:42AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:30AM  GenVec Reports Second Quarter 2014 Financial Results PR Newswire
Jun-16-14 04:16PM  GENVEC INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits EDGAR Online
May-12-14 05:10PM  U.S./Canada daily earnings hits & misses May 12 - 1710 ET Reuters
09:31AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
08:03AM  GenVec sees FY14 cash burn between $5M-$7M at theflyonthewall.com
08:03AM  GenVec reports Q1 EPS (7c), one estimate 4c at theflyonthewall.com
08:00AM  GenVec Reports First Quarter 2014 Financial Results PR Newswire
Mar-28-14 03:02PM  GenVec's CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
10:00AM  GenVec, Inc. Earnings Call scheduled for 10:00 am ET today CCBN
08:55AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:40AM  GenVec Reports Fourth Quarter and 2013 Year-End Financial Results PR Newswire
07:07AM  Q4 2013 GenVec, Inc. Earnings Release - Before Market Open CCBN
Mar-27-14 05:36PM  Why GenVec (GNVC) Stock Is Up In Aftermarket Trading at TheStreet +13.73%
Mar-21-14 08:00AM  GenVec To Release Fourth Quarter And Year-End 2013 Financial Results And Conduct A Conference Call On March 28, 2014 PR Newswire -5.90%
Mar-18-14 05:08PM  GENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
Mar-13-14 08:51AM  GenVec Announces $9 Million Registered Direct Offering PR Newswire -5.34%
Mar-03-14 08:00AM  GenVec to Present at 26th Annual ROTH Conference PR Newswire
Feb-26-14 07:31AM  GENVEC INC Files SEC form 8-K, Other Events EDGAR Online
Feb-24-14 11:37AM  Coverage initiated on GenVec by HC Wainwright Briefing.com
Feb-13-14 06:15AM  GENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exh EDGAR Online
06:00AM  GenVec Achieves Third Milestone In Hearing And Balance Collaboration PR Newswire
Jan-03-14 07:00AM  3 Biotech Stocks Under $10 Triggering Breakouts at TheStreet
Dec-11-13 04:19PM  GENVEC INC Files SEC form 8-K, Other Events EDGAR Online
Nov-27-13 09:40AM  GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Security EDGAR Online
Nov-12-13 09:52AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online -8.03%
07:50AM  GenVec Reports Third Quarter 2013 Financial Results PR Newswire
Oct-23-13 11:47AM  Online Auction for GenVec, Inc. Hosted by Surplus Solutions LLC and The Branford Group Business Wire
Oct-21-13 04:16PM  GENVEC INC Files SEC form 8-K, Other Events EDGAR Online
Oct-07-13 04:15PM  GENVEC INC Files SEC form 8-K, Other Events EDGAR Online
Sep-23-13 07:59AM  GenVec announces dismissal of class actoin lawsuit theflyonthewall.com +35.37%
07:59AM  InPlay: GenVec announces dismissal of class action lawsuit Briefing.com
07:58AM  GenVec Announces Dismissal Of Class Action Lawsuit PR Newswire
Sep-19-13 04:46PM  GENVEC INC Files SEC form 8-K, Shareholder Director Nominations EDGAR Online -9.68%
Sep-13-13 06:02PM  Nasdaq stocks posting largest volume increases AP +22.68%
Sep-05-13 04:42PM  GENVEC INC Files SEC form 8-K, Other Events, Regulation FD Disclosure EDGAR Online -10.42%
Sep-04-13 08:30AM  GenVec Board Restructures Operations and Withdraws Plan of Dissolution PR Newswire +77.78%
Aug-13-13 04:07PM  GENVEC INC Files SEC form 10-Q, Quarterly Report EDGAR Online -9.38%
Aug-08-13 05:27PM  GENVEC INC Files SEC form 8-K, Other Events EDGAR Online
Jul-30-13 09:52AM  GENVEC INC Files SEC form 8-K, Termination of a Material Definitive Agreement EDGAR Online
Jun-28-13 09:49AM  GENVEC INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities EDGAR Online -5.13%
Jun-25-13 09:46AM  GENVEC INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf EDGAR Online +14.29%
Jun-24-13 09:51AM  GENVEC INC Files SEC form 8-K, Other Events EDGAR Online
May-28-13 01:30AM  GENVEC INC Files SEC form 8-K, Other Events EDGAR Online -34.72%
May-10-13 09:10AM  GENVEC INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Apr-26-13 02:22AM  GENVEC INC Files SEC form 8-K, Other Events EDGAR Online
Mar-27-13 06:00PM  UK scientists develop safer foot-and-mouth vaccine at Reuters
Mar-22-13 05:51PM  GenVec Q4 Net Loss Deepens at Motley Fool
01:21PM  GenVec CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha
10:00AM  GenVec, Inc. Earnings Call scheduled for 10:00 am ET today CCBN
07:59AM  GenVec sees FY13 cash burn to be between $8M-$9M theflyonthewall.com
07:58AM  GenVec Reports Fourth Quarter And 2012 Year-End Financial Results PR Newswire
07:07AM  Q4 2012 GenVec, Inc. Earnings Release - Before Market Open CCBN
02:23AM  GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on using its adenovector gene delivery platform to develop a pipeline of therapeutics and vaccines in the United States. The company develops its product candidates through collaborations with various companies and organizations, including Novartis AG, Merial Limited, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of various human and animal health concerns. Its lead product candidate includes CGF166, which is in Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. The company also develops vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, Enterovirus D68, and malaria, as well as vaccines against foot-and-mouth disease in the area of animal health. It has a collaboration agreement with TheraBiologics to develop cancer therapeutics. The company was founded in 1992 and is based in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EcoR1 Capital, LLC10% OwnerMay 27Buy2.399,04021,6201,024,358May 27 06:11 PM
EcoR1 Capital, LLC10% OwnerMay 23Buy2.194,60010,0951,019,696May 27 06:11 PM